For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...
RheoSCAN system is the first device to measure the red blood cell (RBC) aggregating force, CSS, which can be used to detect unidentified diabetic kidney diseases (DKD). DKDs were found to have a ...
In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...
Use of platelet function testing during dual antiplatelet therapy, including a P2Y12 antagonist, in acute coronary syndromes does not improve clinical outcomes. Researchers at King's College London ...
November 10, 2011 (San Francisco, California)— Investigators who explored platelet-function testing for guiding antiplatelet therapy in a low-risk PCI population, who earlier this year had announced ...
Please provide your email address to receive an email when new articles are posted on . Over-the-counter herbal supplements are used by millions of Americans. These agents are largely unregulated; no ...
SEOUL, South Korea, Nov. 9, 2022 /PRNewswire/ -- MEDICA 2022 takes places from 14-17, November 2022 in Dusseldorf, Germany. Throughout the exhibition, RheoMeditech will be located in Hall1, Stand F18.
SEOUL, South Korea, Nov. 9, 2022 /PRNewswire/ -- MEDICA 2022 takes places from 14-17, November 2022 in Dusseldorf, Germany. Throughout the exhibition, RheoMeditech will be located in Hall1, Stand F18.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback